AbbVie Inc (ABBV)

pos +0.00
Today's Range: 64.21 - 65.02 | ABBV Avg Daily Volume: 8,039,400
Last Update: 08/26/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 9.06%
Open: $0.00
Previous Close: $64.72
52 Week Range: $45.45 - $68.12
Oustanding Shares: 1,628,542,359
Market Cap: 105,399,261,474
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 8
Moderate Buy 0 0 0 1
Hold 6 6 6 3
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.23 2.23 2.14 1.81
Latest Dividend: 0.57
Latest Dividend Yield: 3.52%
Dividend Ex-Date: 07/13/16
Price Earnings Ratio: 18.65
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
18.65 18.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.38% 2.33% 48.70%
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 184.50 -0.10 -0.02
Earnings for ABBV:
Revenue 22.86B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.19 $4.81 $5.71
Number of Analysts 8 6 9 10
High Estimate $1.22 $1.23 $4.85 $6.01
Low Estimate $1.17 $1.14 $4.77 $5.35
Prior Year $1.13 $1.13 $4.29 $4.81
Growth Rate (Year over Year) 5.86% 5.46% 12.15% 18.75%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Small biotech tanked on weak earnings, but still seems promising.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
The sector seems to be rebounding after tumbling by more than 40%.
The drug maker continued to rally Monday.
The bifurcation can be seen just by looking at Apple's recent results.
Consider raising your sell stop protection to a close below $61.
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.
Valuations are stretched in certain names and industries, so some profit-taking appears in order.

Columnist Conversations

FIBOCALL: The SPX-cash after Ms. Yellen speaks. The "markets" actually moved today after the FED spoke. Fir...
Finally going to hear the latest views of Yellen today and the market and investor have largely been on hold b...
The BLS revised second quarter 20-16 GDP lower by 0.1% to 1.1%. This should provide adequate cover for the Fe...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.